Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – 9,10-seco- cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
2006-05-30
2006-05-30
Cook, Rebecca (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
9,10-seco- cyclopentanohydrophenanthrene ring system doai
C514S167000, C514S171000, C514S181000
Reexamination Certificate
active
07053074
ABSTRACT:
The present invention relates to methods for preventing the development of epithelial ovarian cancer by administering a Vitamin D compound in an amount capable of increasing apoptosis in non-neoplastic ovarian epithelial cells of the female subject.
REFERENCES:
patent: 3608075 (1971-09-01), Glen et al.
patent: 3957982 (1976-05-01), Lachnit-Fixson et al.
patent: 3969502 (1976-07-01), Lachnit-Fixson
patent: 4390531 (1983-07-01), Edgren
patent: 4530839 (1985-07-01), Pasquale
patent: 4544554 (1985-10-01), Pasquale
patent: 4594340 (1986-06-01), Partridge et al.
patent: 4616006 (1986-10-01), Pasquale
patent: 4621079 (1986-11-01), Lachnit-Fixson et al.
patent: 4628051 (1986-12-01), Pasquale
patent: 4757061 (1988-07-01), Faustini et al.
patent: 4760053 (1988-07-01), Labrie
patent: 4800198 (1989-01-01), DuLuca et al.
patent: 4808578 (1989-02-01), Faustini et al.
patent: 4808616 (1989-02-01), Buzzetti et al.
patent: 4814327 (1989-03-01), Ottow et al.
patent: 4817819 (1989-04-01), Kelly
patent: 4833125 (1989-05-01), Neer et al.
patent: 4840943 (1989-06-01), Buzzetti et al.
patent: 4870069 (1989-09-01), Ottow et al.
patent: 4904650 (1990-02-01), Buzzetti et al.
patent: 4921843 (1990-05-01), Pasquale
patent: 4931283 (1990-06-01), Tsuk
patent: 4933184 (1990-06-01), Tsuk
patent: 4954790 (1990-09-01), Barber
patent: 4962098 (1990-10-01), Boissonneault
patent: 5006518 (1991-04-01), Moguilewsky
patent: 5081114 (1992-01-01), Gourvest et al.
patent: 5086047 (1992-02-01), Gourvest et al.
patent: 5089488 (1992-02-01), Ottow et al.
patent: 5108995 (1992-04-01), Casper
patent: 5115096 (1992-05-01), Shoyab et al.
patent: 5190935 (1993-03-01), Binderup et al.
patent: 5196510 (1993-03-01), Rodwell et al.
patent: 5206229 (1993-04-01), Calverley et al.
patent: 5210081 (1993-05-01), Raveendranath et al.
patent: 5227375 (1993-07-01), Labrie et al.
patent: 5246925 (1993-09-01), DuLuca et al.
patent: 5256421 (1993-10-01), Casper
patent: 5262408 (1993-11-01), Bergink
patent: 5278155 (1994-01-01), Ikekawa et al.
patent: 5280023 (1994-01-01), Ehrlich et al.
patent: 5288717 (1994-02-01), Raveendranath et al.
patent: 5314694 (1994-05-01), Gale et al.
patent: 5362720 (1994-11-01), Labrie
patent: 5364847 (1994-11-01), Labrie et al.
patent: 5373004 (1994-12-01), DeLuca et al.
patent: 5374629 (1994-12-01), Calverley et al.
patent: 5380720 (1995-01-01), DeLuca et al.
patent: 5382573 (1995-01-01), Casper
patent: 5387582 (1995-02-01), Hansen
patent: 5389622 (1995-02-01), Posner et al.
patent: 5401731 (1995-03-01), Calverley et al.
patent: 5411949 (1995-05-01), Neef et al.
patent: 5418228 (1995-05-01), Bennick
patent: 5422119 (1995-06-01), Casper
patent: 5428029 (1995-06-01), Doran et al.
patent: 5434146 (1995-07-01), Labrie et al.
patent: 5446035 (1995-08-01), Neef et al.
patent: 5451574 (1995-09-01), Baggiolini et al.
patent: 5461041 (1995-10-01), Bergink et al.
patent: 5468736 (1995-11-01), Hodgen
patent: 5484782 (1996-01-01), DeLuca et al.
patent: 5486511 (1996-01-01), Weintraub et al.
patent: 5496813 (1996-03-01), Eugster et al.
patent: 5502044 (1996-03-01), Buzzetti et al.
patent: 5512554 (1996-04-01), Baggiolini et al.
patent: 5532228 (1996-07-01), Neef et al.
patent: 5536713 (1996-07-01), Duluca et al.
patent: 5541172 (1996-07-01), Labrie et al.
patent: 5545634 (1996-08-01), Labrie
patent: 5547947 (1996-08-01), Dore et al.
patent: 5554599 (1996-09-01), Grue-Sorenen et al.
patent: 5565439 (1996-10-01), Piazza et al.
patent: 5567695 (1996-10-01), Labrie
patent: 5595970 (1997-01-01), Garfield et al.
patent: 5620705 (1997-04-01), Dong et al.
patent: 5633011 (1997-05-01), Dong et al.
patent: 5716945 (1998-02-01), Grue-Sorensen
patent: 5741786 (1998-04-01), Hamersma et al.
patent: 5747480 (1998-05-01), Gast
patent: 5770227 (1998-06-01), Dong et al.
patent: 5780497 (1998-07-01), Miller et al.
patent: 5783208 (1998-07-01), Yenkateshwaran et al.
patent: 5798345 (1998-08-01), Knutson et al.
patent: 5811416 (1998-09-01), Chwalisz et al.
patent: 5827876 (1998-10-01), Sabatucci
patent: 5852056 (1998-12-01), Samid
patent: 5855906 (1999-01-01), McClay
patent: 5858405 (1999-01-01), Gast
patent: 5876746 (1999-03-01), Jona et al.
patent: 5880137 (1999-03-01), Miller et al.
patent: 5888543 (1999-03-01), Gast
patent: 5891868 (1999-04-01), Cummings et al.
patent: 5898038 (1999-04-01), Yallampalli et al.
patent: 5922349 (1999-07-01), Elliesen et al.
patent: 5922542 (1999-07-01), Ralston et al.
patent: 5948775 (1999-09-01), Koko et al.
patent: 5962444 (1999-10-01), Cook et al.
patent: 5972377 (1999-10-01), Jona et al.
patent: 5985910 (1999-11-01), Miller et al.
patent: 5994337 (1999-11-01), Washburn et al.
patent: 5998137 (1999-12-01), Grainter et al.
patent: 6001846 (1999-12-01), Edwards et al.
patent: 6015805 (2000-01-01), Cook et al.
patent: 6020328 (2000-02-01), Cook et al.
patent: 6028064 (2000-02-01), Rodriguez
patent: 6034074 (2000-03-01), Rodriguez et al.
patent: 6310054 (2001-10-01), Rodriguez
patent: 6319911 (2001-11-01), Rodriguez
patent: 6407082 (2002-06-01), Rodriguez et al.
patent: 6444658 (2002-09-01), Rodriguez et al.
patent: 0 253 607 (1987-07-01), None
patent: 0 253 607 (1987-07-01), None
patent: 0 628 312 (1994-02-01), None
patent: WO 95/26730 (1995-10-01), None
patent: WO 98/10771 (1998-03-01), None
patent: WO98/56389 (1998-12-01), None
patent: PCT/US98/11737 (1999-09-01), None
Need et al., Maturitas, (1986) 8/4 (275-280) Abstract Only.
Christiansen et al., European J. of Clinical Investigation, (Aug. 1981) 11 (4) 305-9. Abstract Only.
Hackh's Chemical Dictionary, 1969m p. 305.
Goodman and Gilman, eds., The Pharmacological Basis of Therapeutics, Chapter 68, 1975, pp. 1423-1447.
Need et al., “Comparison of calcium, calcitrol, ovarian hormones and nandrolone in the treatment of osteoporosis.” Maturitas 8:275-280 (1986).
Muss, H.B., et al., “High-dose progestin therapy for metastic breast cancer”, Annals of Oncology 3:S15-S20 (1992).
Vogel, Charles L., “Hormonal Approaches to Breast Cancer Treatment and Prevention: An Overview”, Seminars in Oncology, vol. 23, No. 4 Supp. 9, 2-9 (1996).
Locker, G.Y., “Hormonal therapy of breast cancer”, Cancer Treatment Reviews 23:221-240 (1998).
Muss, Hyman B., et al., Tamoxifen Versus High-Dose Oral Medroxyprogesterone Acetate as Initial Endocrine Therapy for Patients With Metastatic Breast Cancer: A Piedmont “Oncology Associate Study”, Journal of Clinical Oncology, vol. 12 No. 8 (Aug.), (1994).
Lundgren, S., “Progestins in Breast Cancer Treatment”, Acta Oncologica, Vo. 31 No. 7 709-722 (1992).
Vink-Van Wijngaarden, T., et al. “Inhibition of Breast Cancer Cell Growth by Combined Treatment with Vitamin D3 Analogues and Tamoxifen” Cancer Research 54:711-5717, Nov. 1, 1994.
Christakos, S., “Vitamin D and Breast Cancer”, Diet and Breast Cancer,Chapter 12, 115-118 (1994).
Beer MD, et al., “A Phase I trial of pulse calcitriol in patients with refractory malignancies pulse dosing permits substantial dose escalation”, Cancer vol. 91, Issue 12 pp. 2431-2439 (Jun. 15, 2001).
Gill, P.G. et al., “Randomzied comparison of the efects of tamoxifen, megestrol acetate, or tamoxifen pus megestrol acetate on treatment response and survival in patients with metastatic breast cancer”, Annals of Oncology741-744 (1993).
Bower, M., et al., “Topical calcipotriol treatment in advanced breast cancer”, The Lancet, vol. 337 (Mar. 23, 1991).
Gulliford, T. et al., “A phase I study of the vitamin D analogue EB 1089 in patients with advanced breast and colorectal cancer”, British Journal of Cancer, 6-13, (1998).
Kandouz, M. et al., Antagonism Between Estradiol and Progestin on BCL-2 Expression in Breast-Cancer Cells, Int. J. Cancer: 68, 120-125 (1996).
Vogel, C., “Update on the current use of hormonals as therapy in advanced breast cancer”, Use of hormonals in advanced breast cancer, Anti-Cancer Drugs, 14:265-273 (2003).
Beat, T., “Anastrozole versus progestin/tamoxifen”, European Journal of Cancer 38 Supplement 6, S49- S51
Rodriguez Gustavo C.
Whitaker Regina Salas
Cook Rebecca
New Life Pharmaceuticals Inc.
Nimrod Raymond N.
LandOfFree
Prevention of ovarian cancer by administration of a Vitamin... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Prevention of ovarian cancer by administration of a Vitamin..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Prevention of ovarian cancer by administration of a Vitamin... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3568281